Long-Term Visual Outcomes for a Treat-and-Extend Antivascular Endothelial Growth Factor Regimen in Eyes with Neovascular Age-Related Macular Degeneration: Up to Seven-Year Follow-Up

Table 3

Number of injections per year in the total cohort and among the treatment-naïve and previously treated subgroups.

Timepoint	All eyes		Treatment-naïve subgroup		Previously treated subgroup		value
	n	Number of injections, mean ± SD	n	Number of injections, mean ± SD	n	Number of injections, mean ± SD
Year 1	180	9.1 ± 2.2	121	9.2 ± 2.2	59	9.0 ± 2.3	0.5055
Year 2	178	7.1 ± 2.4	120	6.8 ± 2.5	58	7.7 ± 2.2	0.0372
Year 3	172	6.7 ± 2.9	116	6.3 ± 2.9	56	7.5 ± 2.7	0.0116
Year 4	102	6.2 ± 2.8	56	6.3 ± 2.7	46	6.2 ± 3.1	0.8632
Year 5	72	5.6 ± 3.1	38	5.6 ± 3.3	34	5.1 ± 3.0	0.9684
Year 6	42	5.7 ± 2.8	24	5.3 ± 3.0	18	6.2 ± 2.5	0.2736
Year 7	11	6.1 ± 4.2	6	5.7 ± 4.5	5	6.6 ± 4.3	0.7344